PMID- 38362536
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240217
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 11
DP  - 2024
TI  - Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a 
      case report and review of the literature.
PG  - 1334718
LID - 10.3389/fmed.2024.1334718 [doi]
LID - 1334718
AB  - Immune checkpoint inhibitor (ICI) use has been associated with numerous 
      autoimmune side effects, known as immune related adverse events (irAEs). 
      Cutaneous irAEs are common and affect up to 50% of patients treated with ICIs. 
      There have been an increasing number of cases reported in the literature 
      regarding ICI-induced subacute cutaneous lupus erythematosus (SCLE). ICI-induced 
      SCLE is important to recognize as it can result in a delayed and/or prolonged 
      skin reaction despite treatment discontinuation. We describe a patient with 
      gastro-esophageal adenocarcinoma who developed SCLE following one cycle of 
      nivolumab treatment. A 75-year-old man presented to our clinic with a new 
      photo-distributed rash composed of oval scaly pink papules and plaques involving 
      his chest and arms. Despite treatment with topical corticosteroids, he presented 
      to the emergency department 1 week later with worsening rash. Skin biopsy showed 
      vacuolar interface pattern, along with superficial perivascular lymphocytic 
      infiltrate, consistent with a drug eruption. The clinicopathological presentation 
      was consistent with ICI-induced SCLE. Nivolumab treatment was discontinued due to 
      the severity of the rash. The rash remitted with systemic corticosteroids, high 
      potency topical steroids, and hydroxychloroquine. Unfortunately, the patient 
      developed intraperitoneal metastatic disease, and was enrolled in hospice care. 
      In this paper, we highlight the importance of early identification and treatment 
      of this irAE. A review of the literature, including a discussion on the 
      management of ICI-induced SCLE is also provided.
CI  - Copyright (c) 2024 Khorasanchi, Korman, Manne and Meara.
FAU - Khorasanchi, Adam
AU  - Khorasanchi A
AD  - Division of Medical Oncology, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH, United States.
FAU - Korman, Abraham M
AU  - Korman AM
AD  - Department of Dermatology, The Ohio State University, Columbus, OH, United 
      States.
FAU - Manne, Ashish
AU  - Manne A
AD  - Division of Medical Oncology, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH, United States.
FAU - Meara, Alexa
AU  - Meara A
AD  - Division of Medical Oncology, The Ohio State University Comprehensive Cancer 
      Center, Columbus, OH, United States.
AD  - Division of Rheumatology and Immunology, The Ohio State University, Columbus, OH, 
      United States.
LA  - eng
PT  - Case Reports
DEP - 20240201
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC10867168
OTO - NOTNLM
OT  - case report
OT  - cutaneous lupus erythematosus
OT  - esophageal cancer
OT  - immune checkpoint inhibitor
OT  - literature review
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest. The author(s) declared that they were an editorial board 
      member of Frontiers, at the time of submission. This had no impact on the peer 
      review process and the final decision.
EDAT- 2024/02/16 06:43
MHDA- 2024/02/16 06:44
PMCR- 2024/02/01
CRDT- 2024/02/16 04:00
PHST- 2023/11/07 00:00 [received]
PHST- 2024/01/11 00:00 [accepted]
PHST- 2024/02/16 06:44 [medline]
PHST- 2024/02/16 06:43 [pubmed]
PHST- 2024/02/16 04:00 [entrez]
PHST- 2024/02/01 00:00 [pmc-release]
AID - 10.3389/fmed.2024.1334718 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2024 Feb 1;11:1334718. doi: 10.3389/fmed.2024.1334718. 
      eCollection 2024.